Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Instead of forcing a microbe to create a foreign product through extensive engineering, first identify what it is predisposed to make. Then, apply minimal genetic "nudges" to optimize existing pathways. This "downhill" approach creates a much more efficient and viable R&D process.

The industry's focus on antibodies, which are easy to generate, may be a case of technology dictating the science. Dr. Radvanyi argues that natural ligand-receptor interactions, which often rely on lower affinity and higher avidity, could offer a more nuanced and effective way to modulate immune pathways than high-affinity agonist antibodies.

The discovery-based model of finding highly impactful single targets like HER2 or PD-1 is becoming unsustainable as the low-hanging fruit is picked. The field must shift toward an engineering-first approach, designing complex, multi-functional therapeutics to achieve specific clinical objectives, much like high-tech fields.

Where Lilly pursued a challenging medicinal chemistry approach to make a drug more specific, PureTech's Karuna succeeded with a simpler biological solution. They paired the drug with an existing one that blocked its effects outside the brain, mitigating side effects without altering the core, promising molecule.

A common strategic error in biotech is assuming a therapeutic delivery system that works for one part of the body (e.g., the liver) constitutes a universal 'platform.' In reality, effective platforms must be built organ-by-organ; a system for targeting tumors is fundamentally different from one for T-cells or kidneys.

Navigator Medicines challenges the industry's bias for novel mechanisms. Their strategy is to take a well-validated target (anti-TNF) and innovate by solving its known problems—like immune response, formulation, and dosing—to create a best-in-class therapy. This represents a de-risked approach to innovation.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

Resvita Bio's approach isn't about creating proteins from scratch. Instead, they use machine learning to 'read the book of life comprehensively,' analyzing how different organisms have evolved to solve the same biological problem. This allows them to synthesize nature's best solutions into an ideal therapeutic protein.